Key facts: GSK ends dementia trial; reports positive inhaler results; shares drop 51.4%

TradingView
2025.10.23 01:03
portai
I'm PortAI, I can summarize articles.

On October 21, 2025, GSK plc ended the INFRONT-3 trial for latozinemab, a frontotemporal dementia treatment, due to lack of clinical benefits, despite some positive plasma results.12GSK reported positive phase III results for a low carbon Ventolin inhaler, showing similar safety and efficacy. The new version could cut greenhouse gas emissions by 92%, with a 2026 launch planned.34GSK's shares fell 51.4% to $1.54 after its dementia drug, Latozinemab, failed to show effectiveness in a late-stage trial for frontotemporal dementia.5

  • On October 21, 2025, GSK plc ended the INFRONT-3 trial for latozinemab, a frontotemporal dementia treatment, due to lack of clinical benefits, despite some positive plasma results.12
  • GSK reported positive phase III results for a low carbon Ventolin inhaler, showing similar safety and efficacy. The new version could cut greenhouse gas emissions by 92%, with a 2026 launch planned.34
  • GSK's shares fell 51.4% to $1.54 after its dementia drug, Latozinemab, failed to show effectiveness in a late-stage trial for frontotemporal dementia.5
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.